<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756365</url>
  </required_header>
  <id_info>
    <org_study_id>LOEX 015</org_study_id>
    <nct_id>NCT01756365</nct_id>
  </id_info>
  <brief_title>Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency</brief_title>
  <acronym>CECA</acronym>
  <official_title>Autologous Cultured Corneal Epithelium ( Culture d'épithélium cornéen Autologue CECA) for the Treatment of Unilateral Corneal Lesions Associated With Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <brief_summary>
    <textblock>
      The study &quot; Autologous cultured corneal epithelium (CECA) for the treatment of corneal
      lesions associated with limbal stem cell deficiency&quot; is the first clinical trial of this
      product manufactured at the LOEX laboratory. The culture of corneal epithelium strives to
      produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell
      deficiency. The study is a phase I/phase II study with the goal to evaluate safety and
      efficacy of the CECA graft for the treatment of human patients suffering from limbal stem
      cell deficiency.

      The trial is open to all genders. The inclusion of 5 minors is planned.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anatomic assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Global severity score (Epithelial deficit, corneal opacity, peripheral and central vascularization, integrity of the ocular surface)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation according to Snellen chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of pain</measure>
    <time_frame>1 year</time_frame>
    <description>11 point numerical verbal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Health Utilities Index Mark 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Limbal Stem Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>CECA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical transplantation of CECA</intervention_name>
    <arm_group_label>CECA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All genders

          -  Adults

          -  Minors

          -  LSCD in one or two eyes. A minimum of 1-3 mm2 of undamaged limbus is required for a
             biopsy to be taken without foreseeable adverse consequences for the donor eye

        Exclusion Criteria:

          -  Donor eye not sufficiently healthy to allow for the harvesting of a 1-3 mm2 limbal
             biopsy without foreseeable consequences for the donor eye

          -  Pregnancy

          -  Breast-feeding

          -  Incapacitated person

          -  known allergy to aprotinine (Trasylol (R))

          -  Hypersensibility to bovine proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Bazin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIUSSS de l'Est de l'île de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Biasson, MSc</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>7114</phone_ext>
      <email>pauline.biason.cemtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Isabelle Brunette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre universitaire d'Ophtalmologie CHU de Québec - HSS</name>
      <address>
        <city>Québec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bazin, MD FRCS (C)</last_name>
      <phone>418-682-7573</phone>
    </contact>
    <contact_backup>
      <last_name>Lucie Germain, PhD</last_name>
      <phone>4185254444</phone>
      <phone_ext>61696</phone_ext>
      <email>lucie.germain@fmed.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bazin, MD FRCS (C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Richard Bazin</investigator_full_name>
    <investigator_title>Clinical professor ophtalmology, director of the cornea service</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

